BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 24810923)

  • 1. CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis.
    Sun Y; Mao X; Fan C; Liu C; Guo A; Guan S; Jin Q; Li B; Yao F; Jin F
    Tumour Biol; 2014 Aug; 35(8):7765-73. PubMed ID: 24810923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
    Kang H; Mansel RE; Jiang WG
    Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer.
    Kang H; Watkins G; Parr C; Douglas-Jones A; Mansel RE; Jiang WG
    Breast Cancer Res; 2005; 7(4):R402-10. PubMed ID: 15987445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
    Martinez-Ordoñez A; Seoane S; Cabezas P; Eiro N; Sendon-Lago J; Macia M; Garcia-Caballero T; Gonzalez LO; Sanchez L; Vizoso F; Perez-Fernandez R
    Oncogene; 2018 Mar; 37(11):1430-1444. PubMed ID: 29321662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
    Qiao N; Wang L; Wang T; Li H
    Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CXCL12 in metastasis of human ovarian cancer.
    Jiang YP; Wu XH; Xing HY; DU XY
    Chin Med J (Engl); 2007 Jul; 120(14):1251-5. PubMed ID: 17697577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12.
    Douglass S; Meeson AP; Overbeck-Zubrzycka D; Brain JG; Bennett MR; Lamb CA; Lennard TW; Browell D; Ali S; Kirby JA
    J Pathol; 2014 Sep; 234(1):74-85. PubMed ID: 24870556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells].
    Jiang YP; Wu XH; Xing HY; DU XY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):403-7. PubMed ID: 17697603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Krüppel-like factor 8 activates the transcription of C-X-C cytokine receptor type 4 to promote breast cancer cell invasion, transendothelial migration and metastasis.
    Mukherjee D; Lu H; Yu L; He C; Lahiri SK; Li T; Zhao J
    Oncotarget; 2016 Apr; 7(17):23552-68. PubMed ID: 26993780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.
    Ramos EA; Grochoski M; Braun-Prado K; Seniski GG; Cavalli IJ; Ribeiro EM; Camargo AA; Costa FF; Klassen G
    PLoS One; 2011; 6(12):e29461. PubMed ID: 22220212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.
    Dayer R; Babashah S; Jamshidi S; Sadeghizadeh M
    J Cancer Res Ther; 2018; 14(2):345-350. PubMed ID: 29516917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/CXCR4 pathway.
    Gao XL; Zheng M; Wang HF; Dai LL; Yu XH; Yang X; Pang X; Li L; Zhang M; Wang SS; Wu JB; Tang YJ; Liang XH; Tang YL
    BMC Cancer; 2019 Jul; 19(1):743. PubMed ID: 31357956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.
    Appaiah H; Bhat-Nakshatri P; Mehta R; Thorat M; Badve S; Nakshatri H
    Cancer Biol Ther; 2010 Sep; 10(6):600-14. PubMed ID: 20603605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
    Chinni SR; Yamamoto H; Dong Z; Sabbota A; Bonfil RD; Cher ML
    Mol Cancer Res; 2008 Mar; 6(3):446-57. PubMed ID: 18337451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion.
    Nasser MW; Qamri Z; Deol YS; Smith D; Shilo K; Zou X; Ganju RK
    PLoS One; 2011; 6(9):e23901. PubMed ID: 21915267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL12 promotes CCR7 ligand-mediated breast cancer cell invasion and migration toward lymphatic vessels.
    Hayasaka H; Yoshida J; Kuroda Y; Nishiguchi A; Matsusaki M; Kishimoto K; Nishimura H; Okada M; Shimomura Y; Kobayashi D; Shimazu Y; Taya Y; Akashi M; Miyasaka M
    Cancer Sci; 2022 Apr; 113(4):1338-1351. PubMed ID: 35133060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL12-CXCR4 Axis Promotes Proliferation, Migration, Invasion, and Metastasis of Ovarian Cancer.
    Guo Q; Gao BL; Zhang XJ; Liu GC; Xu F; Fan QY; Zhang SJ; Yang B; Wu XH
    Oncol Res; 2014; 22(5-6):247-58. PubMed ID: 26629936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.
    Wendt MK; Cooper AN; Dwinell MB
    Oncogene; 2008 Feb; 27(10):1461-71. PubMed ID: 17724466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway.
    Zhao S; Wang J; Qin C
    J Exp Clin Cancer Res; 2014 Dec; 33(1):103. PubMed ID: 25471741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.
    Marques CS; Santos AR; Gameiro A; Correia J; Ferreira F
    BMC Cancer; 2018 Jul; 18(1):741. PubMed ID: 30012106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.